11.17

1.06% -0.12

After Hours: 11.17

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $11.17, with a volume of 2.19M. It is down -1.06% in the last 24 hours and down -2.87% over the past month. Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Previous Close:

$11.29

Open:

$11.55

24h Volume:

2.19M

Relative Volume:

1.21

Market Cap:

$1.89B

Revenue:

$68.56M

Net Income/Loss:

$-437.99M

P/E Ratio:

-3.5305

EPS:

-3.1639

Net Cash Flow:

$-396.61M

1W Performance:

+4.78%

1M Performance:

-2.87%

6M Performance:

+23.29%

1Y Performance:

+97.35%

1-Day Range:

$10.95

$11.73

1-Week Range:

$10.33

$11.73

52-Week Range:

$4.815

$11.94

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1064)

Industry

Biotechnology (595)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

367

Twitter

@Vir_Biotech

Next Earnings Date

2026-11-04

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR Vir Biotechnology Inc	11.17	1.80B	68.56M	-437.99M	-396.61M	-3.1639
VRTX Vertex Pharmaceuticals Inc	504.73	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Upgrade	Raymond James	Outperform → Strong Buy
Sep-03-25	Initiated	Evercore ISI	Outperform
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

Oct 01, 2026

Vir Biotechnology, Inc. Announces Chief Financial Officer Changes - marketscreener.com

Oct 01, 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer - biospace.com

Oct 01, 2026

Vir Biotechnology Appoints Aziz Sawaf as EVP and CFO - Contract Pharma

Oct 01, 2026

Vir Biotechnology names Aziz Sawaf as chief financial officer By Investing.com - Investing.com Canada

Oct 01, 2026

A $150K sign-on bonus, contingent on continued employment, awaits Vir Biotechnology (VIR)'s incoming CFO. - Stock Titan

Oct 01, 2026

Raymond James reiterates USD 19.00 target for Vir Biotechnology stock - AD HOC NEWS

Oct 01, 2026

Sep 30, 2026

Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat

Sep 30, 2026

Sep 29, 2026

Vir Biotechnology (NASDAQ:VIR) Nears Key Hepatitis Delta Readout - Kalkine Media

Sep 29, 2026

Vir Biotechnology: Astellas Deal Highlights The Platform's Value - Seeking Alpha

Sep 29, 2026

Sep 28, 2026

Vir Biotechnology (VIR) Poised for Q4 ECLIPSE-1 Data Amid Strate - GuruFocus

Sep 28, 2026

Sep 27, 2026

(VIR) Risk Channels and Responsive Allocation - Stock Traders Daily

Sep 27, 2026

Sep 26, 2026

Bank of America Corp DE Acquires 1,142,539 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat

Sep 26, 2026

Sep 25, 2026